文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

地塞米松对需有创机械通气COVID-19患者呼吸机相关性肺炎和血流感染发生率的影响:一项多中心回顾性研究

Impact of dexamethasone on the incidence of ventilator-associated pneumonia and blood stream infections in COVID-19 patients requiring invasive mechanical ventilation: a multicenter retrospective study.
PubMed 文献 · Ann Intensive Care · 2021-05-31
一句话结论在需有创机械通气的COVID-19患者中,地塞米松未增加呼吸机相关性肺炎或血流感染发生率。

这项在法国三个ICU开展的观察性回顾性研究比较疫情第一波与第二波,纳入2020年3月至11月确诊COVID-19且机械通气≥48小时的151例患者,其中84例接受地塞米松(除1例外均在第二波)。地塞米松组与非地塞米松组呼吸机相关性肺炎发生率分别为63%与57%(p=0.43),血流感染发生率分别为29%与30%(p=0.86),均无显著差异。地塞米松组第28天无通气天数更多(9天 vs 0天,p=0.009),ICU住院时间更短(20天 vs 32天,p=0.01),两组死亡率无差异。作者认为地塞米松可能不能解释重症COVID-19患者中观察到的高呼吸机相关性肺炎和血流感染发生率。

要点

  • 需有创机械通气≥48小时的COVID-19患者中,地塞米松组与非地塞米松组呼吸机相关性肺炎发生率63% vs 57%(p=0.43),无显著差异。
  • 多因素分析未将地塞米松识别为呼吸机相关性肺炎发生的独立危险因素。
  • 血流感染发生率地塞米松组与非地塞米松组分别为29% vs 30%(p=0.86),无显著差异。
  • 地塞米松组第28天无通气天数更多(9(0-21)天 vs 0(0-11)天,p=0.009),ICU住院时间更短(20(11-44)天 vs 32(17-46)天,p=0.01)。
  • 两组死亡率无差异。

适用人群与场景

  • 2020年3月至11月入住法国三个ICU、确诊COVID-19且需要有创机械通气≥48小时的患者。

处置流程与药物剂量

  • 地塞米松组84例接受地塞米松,除1例外均在疫情第二波使用;非地塞米松组67例未接受地塞米松。

研究设计与关键结果

  • 研究类型:多中心观察性回顾性研究,比较疫情第一波与第二波;纳入151例需有创机械通气≥48小时的COVID-19患者,其中84例接受地塞米松。
  • 主要终点:呼吸机相关性肺炎发生率在地塞米松组为63%,非地塞米松组为57%(p=0.43);将死亡、机械通气时长和晚期免疫抑制作为竞争因素时,呼吸机相关性肺炎累积发生率两组无差异(p=0.59)。
  • 多因素分析未将地塞米松识别为呼吸机相关性肺炎发生的独立危险因素。
  • 血流感染发生率地塞米松组29% vs 非地塞米松组30%(p=0.86),无显著差异。
  • 次要终点:地塞米松组第28天无通气天数9(0-21)天 vs 非地塞米松组0(0-11)天(p=0.009);ICU住院时间20(11-44)天 vs 32(17-46)天(p=0.01);两组死亡率无差异。

证据类型、等级与局限

  • 证据类型:多中心观察性回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在需有创机械通气的COVID-19患者中,地塞米松未增加呼吸机相关性肺炎或血流感染发生率,作者认为地塞米松可能不能解释重症COVID-19患者中观察到的高呼吸机相关性肺炎和血流感染发生率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Dexamethasone decreases mortality in patients with severe coronavirus disease 2019 (COVID-19) and has become the standard of care during the second wave of pandemic. Dexamethasone is an immunosuppressive treatment potentially increasing the risk of secondary hospital acquired infections in critically ill patients. We conducted an observational retrospective study in three French intensive care units (ICUs) comparing the first and second waves of pandemic to investigate the role of dexamethasone in the occurrence of ventilator-associated pneumonia (VAP) and blood stream infections (BSI). Patients admitted from March to November 2020 with a documented COVID-19 and requiring mechanical ventilation (MV) for ≥ 48 h were included. The main study outcomes were the incidence of VAP and BSI according to the use of dexamethasone. Secondary outcomes were the ventilator-free days (VFD) at day-28 and day-60, ICU and hospital length of stay and mortality.

RESULTS: Among the 151 patients included, 84 received dexamethasone, all but one during the second wave. VAP occurred in 63% of patients treated with dexamethasone (DEXA+) and 57% in those not receiving dexamethasone (DEXA-) (p = 0.43). The cumulative incidence of VAP, considering death, duration of MV and late immunosuppression as competing factors was not different between groups (p = 0.59). A multivariate analysis did not identify dexamethasone as an independent risk factor for VAP occurrence. The occurrence of BSI was not different between groups (29 vs. 30%; p = 0.86). DEXA+ patients had more VFD at day-28 (9 (0-21) vs. 0 (0-11) days; p = 0.009) and a reduced ICU length of stay (20 (11-44) vs. 32 (17-46) days; p = 0.01). Mortality did not differ between groups.

CONCLUSIONS: In this cohort of COVID-19 patients requiring invasive MV, dexamethasone was not associated with an increased incidence of VAP or BSI. Dexamethasone might not explain the high rates of VAP and BSI observed in critically ill COVID-19 patients.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Gragueb-Chatti I, Lopez A, Hamidi D, et al. Impact of dexamethasone on the incidence of ventilator-associated pneumonia and blood stream infections in COVID-19 patients requiring invasive mechanical ventilation: a multicenter retrospective study. Ann Intensive Care. 2021. PMID: 34057642. doi:10.1186/s13613-021-00876-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。